Sales and adj. EBITDA -1% and +4% vs. ABGSCe -1,900 customer intake q-o-q vs.
Redeye gives a comment on Xavi Solutions Q4 2022 report that was revealed earlier today.
EBIT SEK 8.0m (-25%% vs. ABGSCe 10.7m) Sales-mix driven EBIT deviation Trading at 17x ’23e EV/EBIT o...
33% org growth, but 27% EBIT miss due to OEM+VIP+FX 26% EBIT CAGR 2022-2025e on 30% margins 25-15x E...
Redeye updates its estimates for Mestro, a well-positioned property technology company offering a cl...
Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year).
Redeye updates on GiG ahead of its Q4-results (due 15 February) where we expect a strong quarter on ...
Redeye sees a Q4 report that was uneventful as expected.
Redeye updates on EG7 ahead of its Q4-results (due 17 February) where we expect solid performance on...
We expect Stockwik to present a decent Q4 report on 17 February, and forecast EBITA of SEK 26m still...
Prefab struggles, Installation Services better Lowered margin expectations in Products & Solutions 1...
Weaker-than-expected Q4 due to cancelled large customer FY'23 guidance places ABGSCe at the low end ...
Inför Coors Q4-rapport räknar Analysguiden med ökad omsättning och sekventiellt stärkt lönsamhet.
Rekordstarkt 2022, men tecken på avmattning Nettoomsättningen ökade med 22% till 730 mkr i Q4 y/y, v...
Redeye provides an update on Kontigo Care following its Q4 2022 report.
Sales -4%, EBIT -27% vs. ABGSCe, 33% org sales (ABG 49%) Q1 guidance of ~40% growth y-o-y, but negat...
Redeye’s initial comment on the Q4 report was published earlier this morning.
EBIT SEK 66m (-9% vs. ABGSCe SEK 72m) Q4 numbers imply EBIT downgrades of 2% Trading at 12x '23e EV/...
CPI-PPI gap is shrinking - positive for '23e margins Q4'22e sales up 3%, EBITDA down 8% New bolt-ons...
Q4 estimates nearly unchanged We cut '23e-'24e EBIT by 3-2% 8x '23e EV/EBIT What to look for in Q4'...
